C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
P057 PROSPER: A phase 3 study of enzalutamide in non-metastatic (M0) castration-resistant prostate cancer (CRPC) patients
Axel Heidenreich,Cora N. Sternberg,Karim Fizazi,F. Saad,N.D. Shore,M. Hirmand,Frank Perabo,Z. Khondker,Katharina Modelska,Maha Hussain +9 more
Journal Article
Comparison of the BTA textitstattextsuperscriptTM Test with Voided Urine Cytology and Bladder Wash Cytology in the Diagnosis and Monitoring of Bladder Cancer
Herbert Leyh,Michael Marberger,Pierre Conort,Cora N. Sternberg,Vito Pansadoro,Francesco Pagano,Pierfrancesco Bassi,Laurent Boccon-Gibod,Vincent Ravery,Uwe Treiber,Laura Ishak +10 more
TL;DR: The BTA stat test is considerably more sensitive than cytology in the detection of BC and can replace cytology as an adjunct to cystoscopy in the diagnosis and follow-up of patients with BC.
Journal ArticleDOI
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
Celestia S. Higano,Daniel J. George,Neal D. Shore,Oliver Sartor,Kurt Miller,Peter S. Conti,Cora N. Sternberg,Fred Saad,Juan Pablo Sade,Joaquim Bellmunt,M. R. Smith,Kumari Chandrawansa,Per Sandström,F. Verholen,Bertrand Tombal +14 more
TL;DR: In this paper , the authors performed a global, prospective, observational study of radium-223 in men with mCRPC, where the authors sought to understand longterm safety and treatment patterns in men who received radium223 in real-world clinical practice.
Journal ArticleDOI
A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.
Jones T. Nauseef,M. Sun,Charlene Thomas,Mahelia Bissassar,Amie Patel,Angela Tan,Escarleth Fernandez,Z. Davidson,Tessa A Chamberlain,Kara Earle,Rebecca Wunder,Sandra Huicochea Castellanos,Peter Gregos,Joseph R. Osborne,Karla V. Ballman,Ana M. Molina,Cora N. Sternberg,David M. Nanus,Neil H. Bander,Scott T. Tagawa +19 more
TL;DR: In this paper , a phase I dose-escalation study of 225Ac-J591 was conducted for prostate-specific membrane antigen targeted radiotherapy (PSMA-TRT) in mCRPC patients.